Sangamo Therapeutics Ownership | Who Owns Sangamo Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Sangamo Therapeutics Ownership Summary


Sangamo Therapeutics is owned by 0.14% institutional investors, 1.76% insiders, and 98.10% retail investors. Vanguard group is the largest institutional shareholder, holding 3.94% of SGMO shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.51% of its assets in Sangamo Therapeutics shares.

SGMO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSangamo Therapeutics0.14%1.76%98.10%
SectorHealthcare Stocks 245.07%12.10%-157.17%
IndustryBiotech Stocks 380.48%11.73%-292.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group12.00M3.94%$5.04M
Blackrock4.70M2.61%$1.69M
Two sigma advisers, lp2.11M0.82%$1.42M
D. e. shaw1.17M0.65%$417.78K
Macquarie management400.00K0.12%$99.00K
Meritage portfolio management227.00K0.07%$95.34K
Ameriprise financial75.27K0.04%$26.97K
Hedges asset management125.00K0.04%$52.50K
Rhumbline advisers59.65K0.03%$21.35K
Cubist systematic strategies54.25K0.02%$36.53K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Hedges asset management125.00K0.04%$52.50K
Meritage portfolio management227.00K0.01%$95.34K
Scientech research17.02K0.00%$11.46K
Two sigma advisers, lp2.11M0.00%$1.42M
Sandbox financial partners24.83K0.00%$6.13K
D. e. shaw1.17M0.00%$417.78K
Flow traders u.s.21.50K0.00%$5.00K
Macquarie management400.00K0.00%$99.00K
Cubist systematic strategies54.25K0.00%$36.53K
Woodline partners lp28.86K0.00%$19.43K

Top Buyers

HolderShares% AssetsChange
Two sigma advisers, lp2.11M0.00%901.62K
Vanguard group12.00M0.00%385.23K
Hedges asset management125.00K0.04%125.00K
Ameriprise financial75.27K-63.80K
Meritage portfolio management227.00K0.01%50.00K

Top Sellers

HolderShares% AssetsChange
Armistice capital---40.40M
Vanguard capital management---12.70M
Blackrock4.70M--8.57M
Two sigma investments, lp---6.27M
Balyasny asset management---5.29M

New Positions

HolderShares% AssetsChangeValue
Hedges asset management125.00K0.04%125.00K$52.50K
Flow traders u.s.21.50K0.00%21.50K$5.00K
Scientech research17.02K0.00%17.02K$11.46K
Equitable12.85K-12.85K$5.40K
Point72 europe (london) llp695.00-695.00$468.00

Sold Out

HolderChange
Barclays-1.00
Headlands-5.00
Us bancorp \de\-11.00
Td waterhouse canada-31.00
Srs capital advisors-31.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20267-94.07%533,407-99.49%-0.02%4-93.44%--100.00%
Mar 31, 2026102-8.11%87,227,22440.09%256.17%5118.60%14-58.82%
Dec 31, 202537-68.91%15,567,844-75.13%50.86%15-72.73%8-60.00%
Sep 30, 202543-61.95%19,880,715-60.46%72.02%17-63.83%7-75.86%
Jun 30, 2025118-9.92%51,227,326-2.55%193.50%47-16.07%32-5.88%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF5.65M2.51%1.00
Wasatch Ultra Growth5.59M2.28%1.06M
Vanguard Total Stock Mkt Idx Inv7.96M1.92%-
SPDR® S&P Biotech ETF3.73M1.75%-22.75K
Wasatch Micro Cap2.34M1.12%-3.31M
Vanguard Institutional Extnd Mkt Idx Tr4.46M1.08%-
Vanguard Strategic Small-Cap Equity Inv1.71M0.82%-
Vanguard Explorer Inv1.40M0.67%-
Fidelity Extended Market Index2.10M0.51%-7.66K
Schwab US Small-Cap ETF™1.80M0.43%-131.00

Recent Insider Transactions


DateNameRoleActivityValue
Apr 22, 2026Davis Gregory D Head of Research & TechnologySell$17.69K
Apr 21, 2026Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICERSell$89.18K
Sep 26, 2023BIOGEN INC.-Sell$3.00M
Aug 29, 2022BIOGEN INC.-Sell$2.13M
Aug 29, 2022Biogen MA Inc. Sell$526.52K

Insider Transactions Trends


DateBuySell
2026 Q2-2
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

SGMO Ownership FAQ


Who Owns Sangamo Therapeutics?

Sangamo Therapeutics shareholders are primarily institutional investors at 0.14%, followed by 1.76% insiders and 98.10% retail investors. The average institutional ownership in Sangamo Therapeutics's industry, Biotech Stocks , is 380.48%, which Sangamo Therapeutics falls below.

Who owns the most shares of Sangamo Therapeutics?

Sangamo Therapeutics’s largest shareholders are Vanguard group (12M shares, 3.94%), Blackrock (4.7M shares, 2.61%), and Two sigma advisers, lp (2.11M shares, 0.82%). Together, they hold 7.37% of Sangamo Therapeutics’s total shares outstanding.

Does Blackrock own Sangamo Therapeutics?

Yes, BlackRock owns 2.61% of Sangamo Therapeutics, totaling 4.7M shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.69M$. In the last quarter, BlackRock decreased its holdings by -8.575M shares, a -64.58% change.

Who is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested?

Hedges asset management is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.04% of its assets in 125K Sangamo Therapeutics shares, valued at 52.5K$.

Who is the top mutual fund holder of Sangamo Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Sangamo Therapeutics shares, with 2.51% of its total shares outstanding invested in 5.65M Sangamo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools